, and the 36-month beta value for RCUS is at 0.87. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The average price suggested by analysts for RCUS is $43.08, which is $20.98 above the current market price. The public float for RCUS is 51.46M, and currently, shorts hold a 16.86% of that float. The average trading volume for RCUS on May 26, 2023 was 975.89K shares.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
RCUS) stock’s latest price update
Arcus Biosciences Inc. (NYSE: RCUS)’s stock price has increased by 25.83 compared to its previous closing price of 17.50. However, the company has seen a 20.53% increase in its stock price over the last five trading sessions.
RCUS’s Market Performance
RCUS’s stock has risen by 20.53% in the past week, with a monthly rise of 25.76% and a quarterly rise of 21.39%. The volatility ratio for the week is 4.79% while the volatility levels for the last 30 days are 5.42% for Arcus Biosciences Inc. The simple moving average for the last 20 days is 19.05% for RCUS stock, with a simple moving average of -3.57% for the last 200 days.
RCUS Trading at 21.75% from the 50-Day Moving Average
After a stumble in the market that brought RCUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.05% of loss for the given period.
Volatility was left at 5.42%, however, over the last 30 days, the volatility rate increased by 4.79%, as shares surge +23.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.01% upper at present.
During the last 5 trading sessions, RCUS rose by +20.69%, which changed the moving average for the period of 200-days by -18.33% in comparison to the 20-day moving average, which settled at $18.71. In addition, Arcus Biosciences Inc. saw 6.48% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at RCUS starting from Jarrett Jennifer, who sale 8,729 shares at the price of $16.81 back on Mar 16. After this action, Jarrett Jennifer now owns 406,217 shares of Arcus Biosciences Inc., valued at $146,734 using the latest closing price.
Jarrett Jennifer, the Chief Operating Officer of Arcus Biosciences Inc., sale 1,600 shares at $23.52 during a trade that took place back on Jan 27, which means that Jarrett Jennifer is holding 414,946 shares at $37,632 based on the most recent closing price.
Stock Fundamentals for RCUS
Current profitability levels for the company are sitting at:
- -250.00 for the present operating margin
- +87.50 for the gross margin
The net margin for Arcus Biosciences Inc. stands at -238.39. The total capital return value is set at -32.18, while invested capital returns managed to touch -30.83. Equity return is now at value -41.30, with -20.40 for asset returns.
Based on Arcus Biosciences Inc. (RCUS), the company’s capital structure generated 18.26 points at debt to equity in total, while total debt to capital is 15.44. Total debt to assets is 8.92, with long-term debt to equity ratio resting at 17.81. Finally, the long-term debt to capital ratio is 15.06.
When we switch over and look at the enterprise to sales, we see a ratio of 3.62, with the company’s debt to enterprise value settled at 0.20. The receivables turnover for the company is 0.28 and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.52.
In conclusion, Arcus Biosciences Inc. (RCUS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.